CIAM
BDRX

Caitong International Asset Management’s Biodexa Pharmaceuticals BDRX Stock Holding History

Caitong International Asset Management’s Portfolio BDRX Stock Details BDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15 Buy
+5
New +$17 ﹤0.01% 2573
2026
Q1 		– Hold
0
– – – 2461

Other funds holding BDRX

GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
APW
Allied Private Wealth Boca Raton, Florida $156M AUM
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HHCP
Hilton Head Capital Partners Hilton Head Island, South Carolina $198M AUM
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Caitong International Asset Management's BDRX Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Biodexa Pharmaceuticals (BDRX) in Q2 2026: 5 shares worth $15. The stake represents ﹤0.01% of the portfolio and ranks #2573 among its holdings.

7 funds tracked by Wall St. Rank hold BDRX as of Q2 2026.

  • Caitong International Asset Management held 5 shares of Biodexa Pharmaceuticals worth $15 as of Q2 2026.
  • Biodexa Pharmaceuticals was a new Caitong International Asset Management position in Q2 2026.
  • Biodexa Pharmaceuticals made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2573 holding.
  • 7 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.